ResMed (NYSE:RMD) Full Year 2025 Results

Key Financial Results

• Revenue: US$5.15b (up 9.8% from FY 2024).
• Net income: US$1.40b (up 37% from FY 2024).
• Profit margin: 27% (up from 22% in FY 2024). The increase in margin was driven by higher revenue.
• EPS: US$9.55 (up from US$6.94 in FY 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

ResMed EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.2%.

Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

The company's shares are up 1.5% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on ResMed's balance sheet health.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.